Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 6.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 685,989 shares of the company’s stock after buying an additional 40,692 shares during the period. Geode Capital Management LLC owned about 1.54% of Werewolf Therapeutics worth $1,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $165,000. Rhumbline Advisers acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth approximately $79,000. Acadian Asset Management LLC increased its position in shares of Werewolf Therapeutics by 22.8% during the second quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock worth $516,000 after purchasing an additional 39,413 shares in the last quarter. American Century Companies Inc. raised its stake in Werewolf Therapeutics by 50.7% in the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after purchasing an additional 12,656 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Werewolf Therapeutics by 43.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 160,577 shares of the company’s stock valued at $392,000 after purchasing an additional 48,952 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $1.44 on Friday. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $8.19. The firm has a market cap of $64.17 million, a PE ratio of -0.94 and a beta of 0.38. The company’s 50 day moving average is $1.80 and its two-hundred day moving average is $2.13.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.